Kintor does not have abandoned KX-826 - ANNUAL RESULTS 2023 Product 3/29/2024
The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.
View this post in the Community →
Similar Community Posts Join
6 / 204 resultscommunity Pyrilutamide six months update{ New Progress Pics}
A user shared a six-month update on hair improvement using Pyrilutamide and Minoxidil, noting significant hair regrowth and strength. Some participants questioned the legitimacy of the results and the source of Pyrilutamide.
community KX-826 Phase 3 Failed. Sorry guys...
The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Hope Medicine HMI-115 Phase 1 Success in Australia! 14 hairs/cm2 increase in hair growth.
The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
Related Research
6 / 126 results
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research What's New in Therapy for Male Androgenetic Alopecia?
research Development and Validation of Androgen-Induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
The mouse models are effective for testing new hair loss treatments.
research Androgenetic Alopecia: Therapy Update
There are many treatments for common hair loss, but more trials are needed to decide which are best.
research Efficacy and Safety of Topical KX-826 in Male Subjects with Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study
KX-826 is safe and effectively increases hair count in men with hair loss.
research Comparison of Tissue Loss by Different Punches: A New A-Design
The new A-design punch for hair restoration surgery may lead to smaller scars compared to other types.